Nav: Home

TSRI chemists devise simple method for making sought-after boronic acid-based drugs and other products

April 14, 2017

LA JOLLA, CA -- April 14, 2017 -- Chemists at The Scripps Research Institute (TSRI) have developed a broad and strikingly easy method for synthesizing a class of molecules that have demonstrated value as pharmaceuticals.

The difficulty of preparing these compounds--boronic acids and closely related molecules known as boronate esters--has greatly limited their use in the pharmaceutical industry, and to date there are only three FDA-approved drugs in this category.

With the new method, published this week as a First Release paper the journal Science, chemists can take abundant, inexpensive, structurally diverse compounds known as carboxylic acids and convert them easily into similarly structured boronic acids and related compounds.

"Carboxylic acids are the ideal starting material for synthesizing boronic acids, but until now there hasn't been any method for getting from one to the other," said principal investigator Phil S. Baran, Darlene Shiley Professor of Chemistry at TSRI.

Among the boronic acid-derived molecules Baran and his team made in demonstrating the new method were several novel compounds that are now being investigated further as potential treatments for COPD and other lung disorders.

The development of the new method, known as decarboxylative borylation, follows a breakthrough made a year ago when Baran and his team were studying a reaction commonly used in laboratory chemistry as well as in nature: the amide-bond forming reaction, which among other things, helps stitch amino acids into proteins. "We realized that the principles of amide bond formation, still the most utilized reaction in all of chemical synthesis, could be used to simplify a much broader set of molecule-building tasks," Baran said.

In this case, the insight enables the transformation of virtually any carboxylic acid, whether simple or complex, using just a single reaction step and inexpensive nickel catalysts. The new method essentially replaces a key carbon atom on a carboxylic acid with a boron atom.

"Instead of devoting 95 percent of their effort to introducing a single boron atom, chemists can now easily install boron at any stage," Baran said.

Borylated versions of drug compounds should often have superior properties to their carboxylic acid counterparts. The new method for the first time makes it broadly practical for pharmaceutical chemists to create and investigate these borylated structures. To demonstrate, Baran and his team used the new method to make boronic acid versions of several common drugs, including Lipitor (atorvastatin) and vancomycin.

In a collaboration to demonstrate the translational utility of the discovery, Baran's team and chemists from the California Institute for Biomedical Research (Calibr), also used the method to make boronic acid-based compounds that inhibit a human enzyme known as neutrophil elastase. Immune cells release this enzyme within the lungs during infections and other conditions involving lung inflammation. Elastase is considered a major cause of the lung damage seen in COPD, cystic fibrosis, and related respiratory ailments.

To date, elastase inhibitors developed through other methods have shown limited effectiveness and/or significant side effects, and so far none has been FDA-approved. However, the team found in initial lab-dish tests that their boronic acid-based compounds inhibit elastase more strongly than older elastase-inhibiting compounds. "We found that we could get a significant boost in potency by using a boronic acid group," said study co-author Arnab Chatterjee, director of medicinal chemistry at Calibr.

These boronic acid-based compounds can bind very tightly to their target molecules but in a way that allows them to detach eventually, thus potentially reducing the impact of off-target interactions that cause unwanted side effects.

"The next step is to see how well these compounds perform in animal models," said Chatterjee. "In general, this new method allows us in a practical way to get into this largely unexplored but promising chemical space of borylated compounds, and thus enables us to revisit old targets, such as elastase, that have largely resisted prior drug development efforts."
-end-
The co-lead authors of the paper, "Decarboxylative borylation," were Chao Li and Jie Wang, postdoctoral research associates in the Baran Laboratory. Other co-authors were Lisa M. Barton, Maoqun Tian, David S. Peters, Anthony W. Yu and Ming Yan of TSRI; and Shan Yu, Manoj Kumar and Kristen A. Johnson of Calibr.

Funding was provided by the National Institutes of Health (grant GM-118176), Bristol-Myers Squibb, the China Scholarship Council, the Shanghai Institute of Organic Chemistry, Zhejiang Medicine Co., Pharmaron, Crohn's and Colitis Foundation of America and the German Research Foundation.

About The Scripps Research Institute

The Scripps Research Institute (TSRI) is one of the world's largest independent, not-for-profit organizations focusing on research in the biomedical sciences. TSRI is internationally recognized for its contributions to science and health, including its role in laying the foundation for new treatments for cancer, rheumatoid arthritis, hemophilia, and other diseases. An institution that evolved from the Scripps Metabolic Clinic founded by philanthropist Ellen Browning Scripps in 1924, the institute now employs more than 2,500 people on its campuses in La Jolla, CA, and Jupiter, FL, where its renowned scientists--including two Nobel laureates and 20 members of the National Academies of Science, Engineering or Medicine--work toward their next discoveries. The institute's graduate program, which awards PhD degrees in biology and chemistry, ranks among the top ten of its kind in the nation. In October 2016, TSRI announced a strategic affiliation with the California Institute for Biomedical Research (Calibr), representing a renewed commitment to the discovery and development of new medicines to address unmet medical needs. For more information, see http://www.scripps.edu.

Scripps Research Institute

Related Cystic Fibrosis Articles:

Cystic fibrosis alters the structure of mucus in airways
Cystic fibrosis (CF) alters the structure of mucus produced in airway passages.
Cystic fibrosis study offers new understanding of silent changes in genes
Researchers studying the root cause of cystic fibrosis have made a major advance in our understanding of silent gene changes with implications for the complexity of cystic fibrosis.
New imaging technique shows effectiveness of cystic fibrosis drug
Cystic fibrosis currently has no cure, though a drug approved by the Food and Drug Administration treats the underlying cause of the disease.
New study resolves the structure of the human protein that causes cystic fibrosis
In order to better understand how genetic mutations give rise to cystic fibrosis, researchers need to map the protein responsible for the disorder.
New molecules identified that could help in the fight to prevent cystic fibrosis
New research has identified new molecules that could help in the fight to prevent diseases caused by faulty ion channels, such as cystic fibrosis.
More Cystic Fibrosis News and Cystic Fibrosis Current Events

Best Science Podcasts 2019

We have hand picked the best science podcasts for 2019. Sit back and enjoy new science podcasts updated daily from your favorite science news services and scientists.
Now Playing: TED Radio Hour

Anthropomorphic
Do animals grieve? Do they have language or consciousness? For a long time, scientists resisted the urge to look for human qualities in animals. This hour, TED speakers explore how that is changing. Guests include biological anthropologist Barbara King, dolphin researcher Denise Herzing, primatologist Frans de Waal, and ecologist Carl Safina.
Now Playing: Science for the People

#534 Bacteria are Coming for Your OJ
What makes breakfast, breakfast? Well, according to every movie and TV show we've ever seen, a big glass of orange juice is basically required. But our morning grapefruit might be in danger. Why? Citrus greening, a bacteria carried by a bug, has infected 90% of the citrus groves in Florida. It's coming for your OJ. We'll talk with University of Maryland plant virologist Anne Simon about ways to stop the citrus killer, and with science writer and journalist Maryn McKenna about why throwing antibiotics at the problem is probably not the solution. Related links: A Review of the Citrus Greening...